Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Launches Pharmaceutical Subsidiary

Premium

SALT LAKE CITY--Myriad Genetics recently formed a new subsidiary, Myriad Pharmaceuticals, to develop therapeutic lead compounds for certain common diseases with large potential markets. The new subsidiary will use drug targets discovered with the company's protein interaction technology, ProNet, to identify candidates for preclincal development.

The new subsidiary will be led by Adrian Hobden, former director of biotechnology ventures at Glaxo Wellcome.

Hobden said the new subsidiary "expects that the correct choice of targets, using Myriad's strengths in genetics, bioinformatics, and protein interaction technology, will result in both safer drugs and drugs that are able to prevent either development or further progression of disease."

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.